Cybin (NASDAQ:HELP) Shares Down 5.5% - Here's Why

Key Points

• Cybin shares fell 5.5% to $12.93 in Thursday trading, with volume below the stock’s daily average.
• Insiders bought 385,000 shares worth approximately $4.55 million, while analysts maintained a broadly bullish outlook with a consensus “Buy” rating and an average $48.60 price target.
• Despite the positive signals, Cybin remains a speculative, loss-making clinical-stage biotech: its latest quarterly loss exceeded expectations, and its mental-health drug candidates still require successful trials and regulatory approval.

Cybin Inc. (NASDAQ:HELP - Get Free Report)'s stock price was down 5.5% during trading on Thursday . The company traded as low as $12.80 and last traded at $12.9250. 495,796 shares traded hands during mid-day trading, a decline of 58% from the average daily volume of 1,192,716 shares. The stock had previously closed at $13.68.

Key Cybin News

Here are the key news stories impacting Cybin this week:

• Positive Sentiment: Heavy insider buying signals management confidence. Insiders Paul Glavine and Eric H. L. So collectively purchased 385,000 shares for approximately $4.55 million across transactions from August 31 through September 4. The purchases increased each insider’s existing position by more than 2%. Cybin insider trading report
• Positive Sentiment: Analyst sentiment and price targets are broadly bullish. The company has a reported consensus “Buy” rating and an average price target of $48.60, well above recent trading levels. TD Cowen recently raised its target to $62, while Wells Fargo initiated coverage with an “Overweight” rating and a $16 target. Cybin analyst and insider report
• Positive Sentiment: Upcoming investor conferences may increase visibility. CEO Michael Halstead is scheduled to participate in fireside chats at the H.C. Wainwright conference on September 14 and the Morgan Stanley Global Healthcare Conference on September 16. Investors may look for updates on HLP003, a Phase 3 major-depressive-disorder candidate, and HLP004, a Phase 2 generalized-anxiety-disorder candidate. Helus Pharma Morgan Stanley conference announcement
• Neutral Sentiment: The company is now using the Helus Pharma commercial name. The rebranding could improve visibility for its mental-health programs, but the events themselves do not represent new clinical data or regulatory approvals.
• Negative Sentiment: Cybin remains loss-making and clinically speculative. Its latest quarterly loss missed analyst expectations, with analysts forecasting a larger full-year loss. HLP003 and HLP004 still require successful trials and regulatory approval, and the company cautions that efficacy has not yet been confirmed.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Wells Fargo & Company began coverage on shares of Cybin in a research note on Monday, July 27th. They issued an "overweight" rating and a $16.00 target price for the company. TD Cowen raised their price target on shares of Cybin from $8.00 to $62.00 and gave the company a "buy" rating in a report on Thursday, August 20th. Finally, Wall Street Zen raised shares of Cybin from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 29th. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Cybin presently has an average rating of "Buy" and an average target price of $48.60.

Cybin Stock Down 5.7%

The business has a 50-day simple moving average of $9.70 and a 200-day simple moving average of $6.81. The stock has a market cap of $975.75 million, a P/E ratio of -4.26 and a beta of 0.63.

Cybin (NASDAQ:HELP - Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.91) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.11). On average, analysts predict that Cybin Inc. will post -2.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Cybin

In other news, insider Paul Glavine bought 100,000 shares of the business's stock in a transaction on Thursday, September 3rd. The stock was purchased at an average price of $11.78 per share, with a total value of $1,178,000.00. Following the transaction, the insider directly owned 4,171,252 shares in the company, valued at approximately $49,137,348.56. The trade was a 2.46% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Eric H. L. So purchased 100,000 shares of the firm's stock in a transaction on Friday, September 4th. The shares were purchased at an average price of $12.09 per share, with a total value of $1,209,000.00. Following the completion of the acquisition, the insider directly owned 4,365,014 shares of the company's stock, valued at approximately $52,773,019.26. This trade represents a 2.34% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased a total of 385,000 shares of company stock worth $4,551,100 in the last quarter. Insiders own 15.00% of the company's stock.

Hedge Funds Weigh In On Cybin

Large investors have recently made changes to their positions in the business. AXQ Capital LP acquired a new stake in Cybin in the 2nd quarter valued at approximately $75,000. Pale Fire Capital SE acquired a new position in shares of Cybin during the second quarter worth approximately $1,015,000. Millennium Management LLC boosted its position in shares of Cybin by 1,388.5% in the fourth quarter. Millennium Management LLC now owns 1,028,549 shares of the company's stock valued at $8,414,000 after acquiring an additional 959,448 shares during the period. Osaic Holdings Inc. boosted its position in shares of Cybin by 46.7% in the second quarter. Osaic Holdings Inc. now owns 7,543 shares of the company's stock valued at $63,000 after acquiring an additional 2,400 shares during the period. Finally, Bank of America Corp DE grew its stake in shares of Cybin by 66.8% in the second quarter. Bank of America Corp DE now owns 29,443 shares of the company's stock worth $247,000 after acquiring an additional 11,790 shares during the last quarter. Institutional investors and hedge funds own 17.94% of the company's stock.

About Cybin

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.